This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $169,329 to Wake Forest University Health Sciences (WFUHS) to develop and characterize a transgenic mouse model to study the anti-tumor potential of B cells that recognize tumor-associated carbohydrate antigens (TACAs). The grant aims to: 1) determine the ability of these transgenic B cells to mediate antibody-dependent and independent anti-tumor effects, and 2) identify conditions that stimulate the transgenic B cells to undergo isotype switching and differentiation into plasma cells. The research findings are expected to reveal new strategies to harness TACA-specific B cells for cancer immunotherapy. The project period runs from February 1, 2025 to January 31, 2027.
Generated 2/25/25, 3:09 AM